Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor

Shan Wang, Stephen K. Tyring, Courtney Townsend, B. Mark Evers

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Growth inhibition of human cancers (e.g., endocrine tumors) by interferons (IFNs) has been demonstrated, but the exact cellular mechanisms remain largely undefined. IFNs and other cytokines can activate novel Stat (Signal transducers and activators of transcription) proteins, which translocate to the nucleus to activate target genes. The purpose of this study was to determine the effect of IFN-α and IFN-γ on the Stat pathway using a unique human pancreatic carcinoid tumor, BON, established in our laboratory. Methods: BON cells were treated with IFN-α (500 U/mL) or IFN-γ (500 U/mL); nuclear protein was extracted at selected intervals. Steady state levels of Stat proteins 1, 3, and 5 were measured by Western blot; protein binding was assessed by electrophoretic mobility shift assay (EMSA) using probes containing either the Stat1/Stat3 or Stat5 binding sites. Results: Treatment with IFN-α increased predominantly Stat3 and Stat5 protein levels and binding activities. IFN-γ increased Stat1, 3, and 5 protein levels, with maximal elevations occurring at 24 to 48 hours after addition; Stat3 and 5 binding activities were also increased. Conclusions: We have shown that both IFN-α and IFN-γ can induce Stat protein binding (particularly Stat3 and Stat5) to their cognate DNA consensus sites and increase Stat protein steady state levels in BON cells. Delineating the signaling pathways altered by IFN treatment will provide a better understanding of downstream gene targets and mechanisms for IFN-mediated growth inhibition of endocrine tumors.

Original languageEnglish (US)
Pages (from-to)642-649
Number of pages8
JournalAnnals of Surgical Oncology
Volume5
Issue number7
StatePublished - Oct 1998

Fingerprint

Carcinoid Tumor
Interferons
STAT Transcription Factors
Protein Binding
Endocrine Gland Neoplasms
STAT1 Transcription Factor
Transcription Factor AP-1
Electrophoretic Mobility Shift Assay
Growth
Nuclear Proteins
Transducers
Genes
Neoplasms
Western Blotting
Binding Sites
Cytokines

Keywords

  • Endocrine tumors
  • Interferon
  • Signal transduction pathways
  • Stat proteins

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor. / Wang, Shan; Tyring, Stephen K.; Townsend, Courtney; Evers, B. Mark.

In: Annals of Surgical Oncology, Vol. 5, No. 7, 10.1998, p. 642-649.

Research output: Contribution to journalArticle

Wang, Shan ; Tyring, Stephen K. ; Townsend, Courtney ; Evers, B. Mark. / Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor. In: Annals of Surgical Oncology. 1998 ; Vol. 5, No. 7. pp. 642-649.
@article{ede92ee5fc9943f1bca1206ded1c3d54,
title = "Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor",
abstract = "Background: Growth inhibition of human cancers (e.g., endocrine tumors) by interferons (IFNs) has been demonstrated, but the exact cellular mechanisms remain largely undefined. IFNs and other cytokines can activate novel Stat (Signal transducers and activators of transcription) proteins, which translocate to the nucleus to activate target genes. The purpose of this study was to determine the effect of IFN-α and IFN-γ on the Stat pathway using a unique human pancreatic carcinoid tumor, BON, established in our laboratory. Methods: BON cells were treated with IFN-α (500 U/mL) or IFN-γ (500 U/mL); nuclear protein was extracted at selected intervals. Steady state levels of Stat proteins 1, 3, and 5 were measured by Western blot; protein binding was assessed by electrophoretic mobility shift assay (EMSA) using probes containing either the Stat1/Stat3 or Stat5 binding sites. Results: Treatment with IFN-α increased predominantly Stat3 and Stat5 protein levels and binding activities. IFN-γ increased Stat1, 3, and 5 protein levels, with maximal elevations occurring at 24 to 48 hours after addition; Stat3 and 5 binding activities were also increased. Conclusions: We have shown that both IFN-α and IFN-γ can induce Stat protein binding (particularly Stat3 and Stat5) to their cognate DNA consensus sites and increase Stat protein steady state levels in BON cells. Delineating the signaling pathways altered by IFN treatment will provide a better understanding of downstream gene targets and mechanisms for IFN-mediated growth inhibition of endocrine tumors.",
keywords = "Endocrine tumors, Interferon, Signal transduction pathways, Stat proteins",
author = "Shan Wang and Tyring, {Stephen K.} and Courtney Townsend and Evers, {B. Mark}",
year = "1998",
month = "10",
language = "English (US)",
volume = "5",
pages = "642--649",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "7",

}

TY - JOUR

T1 - Interferon-mediated activation of the STAT signaling pathway in a human carcinoid tumor

AU - Wang, Shan

AU - Tyring, Stephen K.

AU - Townsend, Courtney

AU - Evers, B. Mark

PY - 1998/10

Y1 - 1998/10

N2 - Background: Growth inhibition of human cancers (e.g., endocrine tumors) by interferons (IFNs) has been demonstrated, but the exact cellular mechanisms remain largely undefined. IFNs and other cytokines can activate novel Stat (Signal transducers and activators of transcription) proteins, which translocate to the nucleus to activate target genes. The purpose of this study was to determine the effect of IFN-α and IFN-γ on the Stat pathway using a unique human pancreatic carcinoid tumor, BON, established in our laboratory. Methods: BON cells were treated with IFN-α (500 U/mL) or IFN-γ (500 U/mL); nuclear protein was extracted at selected intervals. Steady state levels of Stat proteins 1, 3, and 5 were measured by Western blot; protein binding was assessed by electrophoretic mobility shift assay (EMSA) using probes containing either the Stat1/Stat3 or Stat5 binding sites. Results: Treatment with IFN-α increased predominantly Stat3 and Stat5 protein levels and binding activities. IFN-γ increased Stat1, 3, and 5 protein levels, with maximal elevations occurring at 24 to 48 hours after addition; Stat3 and 5 binding activities were also increased. Conclusions: We have shown that both IFN-α and IFN-γ can induce Stat protein binding (particularly Stat3 and Stat5) to their cognate DNA consensus sites and increase Stat protein steady state levels in BON cells. Delineating the signaling pathways altered by IFN treatment will provide a better understanding of downstream gene targets and mechanisms for IFN-mediated growth inhibition of endocrine tumors.

AB - Background: Growth inhibition of human cancers (e.g., endocrine tumors) by interferons (IFNs) has been demonstrated, but the exact cellular mechanisms remain largely undefined. IFNs and other cytokines can activate novel Stat (Signal transducers and activators of transcription) proteins, which translocate to the nucleus to activate target genes. The purpose of this study was to determine the effect of IFN-α and IFN-γ on the Stat pathway using a unique human pancreatic carcinoid tumor, BON, established in our laboratory. Methods: BON cells were treated with IFN-α (500 U/mL) or IFN-γ (500 U/mL); nuclear protein was extracted at selected intervals. Steady state levels of Stat proteins 1, 3, and 5 were measured by Western blot; protein binding was assessed by electrophoretic mobility shift assay (EMSA) using probes containing either the Stat1/Stat3 or Stat5 binding sites. Results: Treatment with IFN-α increased predominantly Stat3 and Stat5 protein levels and binding activities. IFN-γ increased Stat1, 3, and 5 protein levels, with maximal elevations occurring at 24 to 48 hours after addition; Stat3 and 5 binding activities were also increased. Conclusions: We have shown that both IFN-α and IFN-γ can induce Stat protein binding (particularly Stat3 and Stat5) to their cognate DNA consensus sites and increase Stat protein steady state levels in BON cells. Delineating the signaling pathways altered by IFN treatment will provide a better understanding of downstream gene targets and mechanisms for IFN-mediated growth inhibition of endocrine tumors.

KW - Endocrine tumors

KW - Interferon

KW - Signal transduction pathways

KW - Stat proteins

UR - http://www.scopus.com/inward/record.url?scp=0031756403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031756403&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 642

EP - 649

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 7

ER -